Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT05603728

Exactech Shoulder Post Market Clinical Follow-up Study

Exactech Shoulder Post Market Clinical Follow-up Study — Recruiting • Infectious Disease • NCT05603728.

📅 17 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05603728
Start
2007-07-19
Completion
2030-12-31
ClinicaliQ Trial Snapshot
  • Exactech Shoulder Post Market Clinical Follow-up Study — Recruiting • Infectious Disease • NCT05603728.
  • Long-term safety and performance study of Exactech shoulder replacements, following patients for at least 10 years.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed. Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections Lead Sponsor: Exactech Planned Enrollment: 20000 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review
Infectious Disease · MHRA · 20 Oct 2026
IXCHIQ chikungunya vaccine marketing authorisation withdrawn in UK following CHM safety review, indicating benefit-risk profile no longer favourable Clinicians should cease prescribing…
View brief →
Clinical Brief
Covid vaccine compensation scheme set for overhaul after Inquiry criticism
Infectious Disease · BBC Health · 16 Oct 2026
The UK Covid vaccine compensation scheme faces significant reform following critical findings from an official Inquiry, indicating current provisions are inadequate for…
View brief →
Clinical Brief
Flu levels low at start of season but higher than previous 4 years
Infectious Disease · UKHSA · 08 Oct 2026
Early signs suggest the 2024/25 flu season may start sooner than recent years, though current levels remain low—eligible patients should be prioritised…
View brief →
Clinical Brief
First person gets new experimental vaccine for Ebola
Infectious Disease · BBC Health · 24 Jul 2026
A new experimental Ebola vaccine has entered human trials, with a UK volunteer as the first recipient, representing progress toward preventing this…
View brief →
Clinical Brief
Ebola vaccine made in UK now ready for trials
Infectious Disease · BBC Health · 13 Jul 2026
UK-developed Ebola vaccine progresses to human trials, potentially providing another immunisation option against a high-mortality infectious disease Clinical trials will generate essential…
View brief →
Clinical Brief
‘My eyelids became infected – I was scared to sleep’
Infectious Disease · BBC Health · 23 Sep 2026
Key Takeaways for Clinical Practice Unregulated cosmetic tourism carries significant infection risks – patients undergoing blepharoplasty abroad face complications including serious eyelid…
View brief →